Suchergebnisse - "Usmani, Saad Z"

PubPharm (59)

1

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

2

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

enthalten in: Advances in therapy | 2024

von Durie, B. | Kumar, S. | Ammann, E. | +5

3

Daratumumab for patients with myeloma with early or late relapse after initial therapy : subgroup analysis of CASTOR and POLLUX

enthalten in: Blood advances | 2024

von Spencer, A. | Moreau, P. | Mateos, M. | +17

4

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma : TAURUS Chart Review Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Gordan, L. | Tan, C. | Vescio, R. | +12

5

Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Lonial, S. | Bowser, A. | Chari, A. | +3

6

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

7

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

enthalten in: Blood advances | 2023

von Usmani, S. | Quach, H. | Mateos, M. | +7

8

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Dimopoulos, M. | Oriol, A. | Nahi, H. | +19

9

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma : Findings from the MASTER and GRIFFIN Trials

enthalten in: Transplantation and cellular therapy | 2023

von Chhabra, S. | Callander, N. | Watts, N. | +34

10

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study

enthalten in: Leukemia & lymphoma | 2023

von Nahi, H. | Usmani, S. | Mateos, M. | +10

1
2
3
4
5
6
Nächster »
[6]